MA50674A - Benzamides substitués 1,3-thiazol-2-yl - Google Patents

Benzamides substitués 1,3-thiazol-2-yl

Info

Publication number
MA50674A
MA50674A MA050674A MA50674A MA50674A MA 50674 A MA50674 A MA 50674A MA 050674 A MA050674 A MA 050674A MA 50674 A MA50674 A MA 50674A MA 50674 A MA50674 A MA 50674A
Authority
MA
Morocco
Prior art keywords
thiazol
substituted benzamides
benzamides
substituted
Prior art date
Application number
MA050674A
Other languages
English (en)
Other versions
MA50674B1 (fr
Inventor
Nico Bräuer
Adam Davenport
Oliver Martin Fischer
Anne-Marie Godinho-Coelho
Jürgen Klar
Jens Nagel
Ioana Neagoe
Andrea Rotgeri
Antje Rottmann
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52015966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50674(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA50674A publication Critical patent/MA50674A/fr
Publication of MA50674B1 publication Critical patent/MA50674B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA50674A 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl MA50674B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196954 2014-12-09

Publications (2)

Publication Number Publication Date
MA50674A true MA50674A (fr) 2021-03-31
MA50674B1 MA50674B1 (fr) 2022-11-30

Family

ID=52015966

Family Applications (2)

Application Number Title Priority Date Filing Date
MA50674A MA50674B1 (fr) 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl
MA41135A MA41135B1 (fr) 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA41135A MA41135B1 (fr) 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl

Country Status (42)

Country Link
US (5) US10174016B2 (fr)
EP (2) EP3230281B1 (fr)
JP (2) JP6544665B2 (fr)
KR (2) KR102548799B1 (fr)
CN (2) CN110256418B (fr)
AR (2) AR102948A1 (fr)
AU (1) AU2015359626B2 (fr)
BR (1) BR112017012327B1 (fr)
CA (1) CA2969952A1 (fr)
CL (1) CL2017001488A1 (fr)
CO (1) CO2017005742A2 (fr)
CR (2) CR20170242A (fr)
CU (1) CU24411B1 (fr)
CY (2) CY1124486T1 (fr)
DK (2) DK3587417T3 (fr)
DO (2) DOP2017000137A (fr)
EA (2) EA034273B1 (fr)
EC (1) ECSP17036253A (fr)
ES (2) ES2908822T3 (fr)
HR (2) HRP20220371T1 (fr)
HU (2) HUE058009T2 (fr)
IL (6) IL252665B (fr)
JO (2) JOP20150301B1 (fr)
LT (2) LT3230281T (fr)
MA (2) MA50674B1 (fr)
MX (2) MX377651B (fr)
MY (1) MY192690A (fr)
NI (1) NI201700073A (fr)
NZ (1) NZ761161A (fr)
PE (2) PE20220253A1 (fr)
PH (1) PH12017501079A1 (fr)
PL (2) PL3587417T3 (fr)
PT (2) PT3230281T (fr)
RS (2) RS63014B1 (fr)
SG (2) SG10202012274RA (fr)
SI (2) SI3230281T1 (fr)
SV (1) SV2017005461A (fr)
TN (1) TN2017000244A1 (fr)
TW (2) TWI716371B (fr)
UA (1) UA120382C2 (fr)
UY (1) UY36422A (fr)
WO (1) WO2016091776A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058009T2 (hu) * 2014-12-09 2022-06-28 Bayer Ag 1,3-Tiazol-2-il szubsztituált benzamid-származékok
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN106588785A (zh) * 2016-12-02 2017-04-26 山东吉田香料股份有限公司 一种乙酰基吡嗪的制备方法
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
WO2019219674A1 (fr) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses
CA3100096A1 (fr) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft Benzamides a substitution 1,3-thiazol-2-yl pour le traitement de maladies associees a la sensibilisation de fibres nerveuses
CN113559104A (zh) 2018-10-05 2021-10-29 盐野义制药株式会社 慢性咳嗽治疗用药物
CA3115939A1 (fr) * 2018-10-10 2020-04-16 Bellus Health Cough Inc. Traitement du prurit avec des antagonistes des recepteurs p2x3
AU2020228760A1 (en) * 2019-02-25 2021-09-23 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment with P2X3 modulators
JP7611848B2 (ja) * 2019-04-05 2025-01-10 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性なジアジン－アミド化合物
BR112021020386A2 (pt) * 2019-04-11 2021-12-07 Syngenta Crop Protection Ag Compostos de diazina-amida ativos pesticidamente
CN114222741B (zh) 2019-05-31 2025-12-30 奇斯药制品公司 作为p2x3抑制剂的吡啶并嘧啶类衍生物
BR112021022099A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
EP3757103A1 (fr) 2019-06-27 2020-12-30 Bayer AG Analogues de 3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide pour le traitement des maladies neurogeniques
CN113082023B (zh) * 2019-12-23 2024-03-01 武汉朗来科技发展有限公司 P2x3抑制剂和p2x4抑制剂的药物组合及其应用
AU2021282039A1 (en) * 2020-05-25 2022-12-01 The National Institutes of Pharmaceutical R&D Co., Ltd. Arylformamide compound and preparation method and medical use thereof
WO2022063205A1 (fr) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 Composé aryl formamide, son procédé de préparation et ses utilisations médicales
WO2022068930A1 (fr) * 2020-09-30 2022-04-07 武汉人福创新药物研发中心有限公司 Composé benzamide et son utilisation
AU2021388923A1 (en) 2020-11-27 2023-05-25 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
KR20230113289A (ko) 2020-11-27 2023-07-28 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 프탈라진 유도체
JP2023550830A (ja) 2020-11-27 2023-12-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としての（アザ）キノリン４－アミン誘導体
CN114591317A (zh) * 2020-12-04 2022-06-07 武汉人福创新药物研发中心有限公司 P2x3抑制剂及其用途
WO2022253943A1 (fr) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Formes cristallines de 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}-benzamide
WO2022253945A1 (fr) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Formes posologiques pharmaceutiques comprenant du 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}-benzamide
CN116396285A (zh) * 2022-01-04 2023-07-07 上海华汇拓医药科技有限公司 氘代四氢呋喃类化合物制备及其应用
US12024285B1 (en) 2022-03-10 2024-07-02 Skypad Tech, Inc. Modular mobility system including thrusters movably connected to a support structure
WO2023185931A1 (fr) * 2022-03-29 2023-10-05 人福医药集团股份公司 Composé inhibiteur de p2x3, sel de celui-ci, polymorphe de celui-ci et utilisation associée
JP2026504260A (ja) * 2022-12-22 2026-02-04 人福医薬集団股▲分▼公司 Ｐ２ｘ３阻害剤を製造する方法
CN121368584A (zh) 2023-05-22 2026-01-20 奇斯药制品公司 用于制备p2x3抑制剂的方法及中间体
CN117777048B (zh) * 2023-09-25 2024-09-20 上海科利生物医药有限公司 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法
TW202525285A (zh) * 2023-12-29 2025-07-01 大陸商人福醫藥集團股份公司 Ｐ２ｘ３受體拮抗劑的固體分散體及其製備方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013595A (es) 2005-05-04 2008-01-24 Renovis Inc Compuestos heterociclicos fusionados y composiciones y usos de estos.
EP2592070B1 (fr) 2006-06-29 2016-08-31 F. Hoffmann-La Roche AG Arylamides de tétrazole substitués
US8501933B2 (en) 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
EP2091927B1 (fr) * 2006-11-09 2011-07-20 F. Hoffmann-La Roche AG Arylamides substituées thiazole et oxazole
CA2682162C (fr) 2007-04-02 2016-05-10 Renovis, Inc. Composes heterocycliques fusionnes avec pyrid-2-yl, et leurs compositions et utilisations
JP5498374B2 (ja) 2007-04-17 2014-05-21 エボテック・アーゲー ２−シアノフェニル縮合複素環式化合物および組成物、ならびにその使用
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
WO2008154601A1 (fr) * 2007-06-12 2008-12-18 Genelabs Technologies, Inc. Inhibiteurs anti-viraux et procédés d'utilisation
CA2703909A1 (fr) 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. Antagonistes du recepteur p2x3 utilises dans le traitement de la douleur
AU2008319309B2 (en) 2007-10-31 2012-09-06 Merck Sharp & Dohme Llc P2X3 receptor antagonists for treatment of pain
EP2234989B1 (fr) 2007-12-17 2014-08-13 F. Hoffmann-La Roche AG Nouveaux arylamides substitués par tétrazole et leur utilisation comme antagonistes des recepteurs purinergiques p2x3 et/ou p2x2/3
ES2542245T3 (es) 2007-12-17 2015-08-03 F. Hoffmann-La Roche Ag Derivados de arilamida sustituido con triazol y su utilización como antagonistas del receptor purinérgico P2x3 y/o P2x2/3
ES2417182T3 (es) 2007-12-17 2013-08-06 F. Hoffmann-La Roche Ag Nuevas arilamidas sustituidas con pirazol
CA2708791C (fr) 2007-12-17 2016-06-21 F. Hoffmann-La Roche Ag Arylamides a imidazole substitue et leurs utilisations comme antagonistes du recepteur p2x
MX2010009561A (es) 2008-02-29 2010-09-24 Renovis Inc Compuestos amida, composiciones y usos de los mismos.
CA2737038A1 (fr) 2008-09-18 2010-03-25 Evotec Ag Composes amides, compositions et utilisations des composes et compositions
ES2534199T3 (es) * 2008-10-31 2015-04-20 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
EP2379518B1 (fr) 2008-12-16 2014-05-07 F. Hoffmann-La Roche AG Arylamides à substitution thiadiazole
CN102574778B (zh) 2009-06-22 2015-01-07 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
EP2445889B1 (fr) 2009-06-22 2016-08-10 F.Hoffmann-La Roche Ag Nouveaux arylamides substitués par benzoxazolone
CN103221047B (zh) 2010-01-13 2014-12-17 坦颇罗制药股份有限公司 化合物和方法
WO2013009810A1 (fr) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Méthodes de traitement
WO2013173441A2 (fr) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Inhibiteurs d'homologue d'activateur de zeste 2
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
US9598409B2 (en) 2013-01-31 2017-03-21 Neomed Institute Imidazopyridine compounds and uses thereof
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
HUE058009T2 (hu) 2014-12-09 2022-06-28 Bayer Ag 1,3-Tiazol-2-il szubsztituált benzamid-származékok
CA3100096A1 (fr) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft Benzamides a substitution 1,3-thiazol-2-yl pour le traitement de maladies associees a la sensibilisation de fibres nerveuses
WO2019219674A1 (fr) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses
EP3757103A1 (fr) 2019-06-27 2020-12-30 Bayer AG Analogues de 3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide pour le traitement des maladies neurogeniques

Also Published As

Publication number Publication date
MX387478B (es) 2025-03-18
IL252665B (en) 2019-10-31
NZ761161A (en) 2024-04-26
DK3230281T3 (da) 2021-08-16
CR20210108A (es) 2021-04-27
SI3587417T1 (sl) 2022-04-29
WO2016091776A1 (fr) 2016-06-16
HUE058009T2 (hu) 2022-06-28
UA120382C2 (uk) 2019-11-25
EA201891120A1 (ru) 2018-10-31
BR112017012327A2 (pt) 2018-02-27
BR112017012327A8 (pt) 2021-02-23
MX2020005909A (es) 2021-10-28
US10472354B2 (en) 2019-11-12
CN110256418B (zh) 2023-01-20
CN107207507A (zh) 2017-09-26
CA2969952A1 (fr) 2016-06-16
CN107207507B (zh) 2020-11-06
EA032312B1 (ru) 2019-05-31
KR102548799B1 (ko) 2023-06-27
TW202130637A (zh) 2021-08-16
IL269467B (en) 2020-08-31
EP3587417B1 (fr) 2022-01-05
CL2017001488A1 (es) 2018-02-23
HRP20211002T1 (hr) 2021-09-17
DK3587417T3 (da) 2022-03-28
PL3230281T3 (pl) 2021-12-13
CN110256418A (zh) 2019-09-20
ES2908822T3 (es) 2022-05-04
IL283979A (en) 2021-07-29
TW201629053A (zh) 2016-08-16
NZ733108A (en) 2022-03-25
SV2017005461A (es) 2018-04-30
KR20230098368A (ko) 2023-07-03
CO2017005742A2 (es) 2017-09-20
US20230053411A1 (en) 2023-02-23
SG10202012274RA (en) 2021-01-28
IL252665A0 (en) 2017-08-31
PE20220253A1 (es) 2022-02-16
AR102948A1 (es) 2017-04-05
IL283979B (en) 2022-04-01
JOP20230073A1 (ar) 2016-06-09
TWI780562B (zh) 2022-10-11
US20180118731A1 (en) 2018-05-03
CY1125083T1 (el) 2023-06-09
US20180093980A1 (en) 2018-04-05
IL275183A (en) 2020-07-30
EA201791261A1 (ru) 2017-12-29
US20200131169A1 (en) 2020-04-30
EP3587417B9 (fr) 2022-03-30
RS62227B1 (sr) 2021-09-30
MA50674B1 (fr) 2022-11-30
NI201700073A (es) 2017-10-24
US10174016B2 (en) 2019-01-08
AU2015359626A1 (en) 2017-06-29
PL3587417T3 (pl) 2022-06-13
BR112017012327B1 (pt) 2023-04-11
HRP20220371T1 (hr) 2022-05-13
IL275183B (en) 2021-06-30
CR20170242A (es) 2018-02-02
JP2017537122A (ja) 2017-12-14
JOP20150301B1 (ar) 2023-09-17
UY36422A (es) 2016-06-30
AU2015359626B2 (en) 2020-07-23
IL269661A (en) 2019-11-28
PH12017501079A1 (en) 2017-10-18
MA41135B1 (fr) 2021-10-29
LT3587417T (lt) 2022-02-10
JP2019059742A (ja) 2019-04-18
HUE055290T2 (hu) 2021-11-29
TWI716371B (zh) 2021-01-21
ECSP17036253A (es) 2017-06-30
JP6544665B2 (ja) 2019-07-17
LT3230281T (lt) 2021-07-12
KR20170093203A (ko) 2017-08-14
ES2882952T3 (es) 2021-12-03
PT3587417T (pt) 2022-03-16
RS63014B1 (sr) 2022-04-29
TN2017000244A1 (en) 2018-10-19
AR119761A2 (es) 2022-01-12
DOP2018000182A (es) 2018-09-15
PE20180227A1 (es) 2018-01-31
MX2017007658A (es) 2018-08-01
SI3230281T1 (sl) 2021-08-31
CU20170077A7 (es) 2017-11-07
JP6647371B2 (ja) 2020-02-14
US20190185466A1 (en) 2019-06-20
IL269661B (en) 2020-07-30
IL269468A (en) 2019-11-28
EA034273B1 (ru) 2020-01-23
US10202369B2 (en) 2019-02-12
CY1124486T1 (el) 2022-07-22
DOP2017000137A (es) 2017-07-31
EP3230281A1 (fr) 2017-10-18
IL269467A (en) 2019-11-28
MY192690A (en) 2022-09-01
SG11201704717VA (en) 2017-08-30
PT3230281T (pt) 2021-08-19
CU24411B1 (es) 2019-05-03
EP3230281B1 (fr) 2021-05-26
EP3587417A1 (fr) 2020-01-01
IL269468B (en) 2020-06-30
US11142523B2 (en) 2021-10-12
MX377651B (es) 2025-03-11

Similar Documents

Publication Publication Date Title
IL283979B (en) 3,1-thiazol-2-yl converted benzamides
FIC20230006I1 (fi) Vutrisiraani
PL3345230T3 (pl) Podwójny perowskit
DK3040326T3 (da) Haloolefin-baseret sammensætning
FR3024363B1 (fr) Composition thermogelifiable
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
KR20180084876A (ko) 내플라즈마성 부재
DE112015001664A5 (de) Betätigungsaktuator
PT3092003T (pt) Novo anticorpo anti-netrina 1
CL2017000639A1 (es) Composición
DE112015005041A5 (de) Gargerätevorrichtung
SMT202200213T1 (it) Nuovi antiestrogeni eterociclici
DE102014000623A8 (de) Halbhohlnietelement
EP3384016A4 (fr) Phagémides modifiés
HUE070090T2 (hu) Összetétel
DK3199160T3 (da) Vandig sammensætning
DK3217964T3 (da) Sammensætning
FR3019552B1 (fr) Composition filmogene
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
DE112015001633A5 (de) Betätigungsaktuator
FR3020039B1 (fr) Aerodyne
ES1098331Y (es) Abaco mejorado
DE102014112481A8 (de) Axialfederanordnung
DE112014006499A5 (de) Umfüllbehälter
CO7010086U1 (es) Conte-box